Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker Corporation (Nasdaq: BRKR) launched a new VIP-HESI ion source at the virtual 4D-Metabolomics™ eXceed Symposium, enhancing sensitivity gains by up to 16-fold for various small molecule applications. The VIP-HESI can be integrated with the timsTOF Pro 2 platform, improving quantitative analyses in diverse fields such as food and environmental safety. Bruker also introduced METLIN-4D, a CCS library with over 10,000 reference compounds, and CCS-Predict Pro, an algorithm for predicting CCS values, enhancing bioinformatics capabilities. The updates aim to streamline and increase the accuracy of 4D-Metabolomics and 4D-Lipidomics.
Bruker Corporation (Nasdaq: BRKR) held its Virtual Investor Day, outlining strategies and Project Accelerate 2.0 initiatives aimed at growth in proteomics and spatial biology. For FY 2021, the company anticipates revenue growth of 16% to 18%, driven by a 3% foreign currency tailwind. Non-GAAP EPS is projected between $1.84 and $1.89, up 36% to 40% year-over-year. Additionally, Bruker aims for revenues of $2.7 to $3.0 billion by FY 2024, with operating margins between 20.7% and 21.5%, showcasing long-term growth potential.
Bruker Corporation (Nasdaq: BRKR) will hold a Virtual Investor Day on June 17, 2021, at 10:00 AM EDT. This event, conducted entirely online, aims to present the company's strategies and initiatives under Project Accelerate 2.0. Attendees can expect insights from the Executive Leadership Team and an opportunity for a live Q&A session. The broadcast will conclude at 1:00 PM EDT. Investors can access the event via the Investor Relations website, and a replay will be available post-event.
Bruker Corporation (Nasdaq: BRKR) has launched the FluoroType SARS-CoV-2 varID Q assay, a new mid-plex PCR panel capable of detecting multiple SARS-CoV-2 variants simultaneously. This CE-IVD marked assay boasts an impressive sensitivity of 98% and 100% specificity, effectively identifying key mutations of the virus. It quantifies viral load in standardized International Units, providing critical insights into patient infectiousness. The assay enhances laboratory efficiency, offering quicker results and lower operational costs compared to sequencing techniques.
Bruker Corporation (Nasdaq: BRKR) launched two new timsTOF instruments at its virtual 4D-Proteomics™ eXceed Symposium. The timsTOF trueSCP enhances quantitative single-cell proteomics, achieving 1,500 proteins per cell, while the timsTOF Pro 2 boasts advanced capabilities for unbiased 4D-Proteomics, identifying over 6,000 proteins and 60,000 unique peptides. New PaSER software supports real-time peptide sequencing and CCS-enabled bioinformatics, improving identification accuracy. CEO Frank H. Laukien emphasized the significance of these innovations for advancing cancer detection and personalized therapy.
A recent clinical research collaboration has explored transient and persistent systemic changes in COVID-19 patient blood samples, revealing biochemical abnormalities related to long COVID symptoms that can persist for months. Using an innovative assay platform of NMR spectroscopy and mass spectrometry, the study identified that over 57% of mildly affected COVID-19 patients experience ongoing health issues three months post-infection. The research emphasizes the need for longitudinal studies to understand future health risks better.
Bruker Corporation (Nasdaq: BRKR) announced a new share repurchase authorization for up to $500 million over two years, starting May 13, 2021. This initiative reflects the company's confidence in its long-term prospects. The repurchase may occur through various methods and can be suspended at any time. Additionally, Bruker declared a quarterly cash dividend of $0.04 per share, set for June 18, 2021, to stockholders of record as of June 1, 2021.
Bruker Corporation (Nasdaq: BRKR) has authorized a new share repurchase plan of up to $500 million over two years starting May 13, 2021. This decision reflects the company's confidence in its long-term prospects. Shares may be repurchased via open market transactions or trading plans under Rule 10b5-1. Additionally, Bruker declared a quarterly cash dividend of $0.04 per share, payable on June 18, 2021, to stockholders of record as of June 1, 2021.
Bruker Corporation has announced that its 1H-NMR spectroscopy has been officially incorporated by the International Organization of Vine and Wine (OIV) for quantifying key wine parameters such as glucose and acidity. This advancement allows for simultaneous and accurate measurement of 53 compounds in a single automated process, addressing the demand for authenticity in wine supply chains. Bruker's NMR Wine-Profiling™ 4.0 enhances supply chain verification and counters fraud, marking a significant innovation in the wine industry.
Bruker Corporation (Nasdaq: BRKR) announced its participation in three upcoming virtual healthcare conferences. The events include the BofA Securities 2021 Health Care Conference on May 11, 2021, the UBS Global Healthcare Virtual Conference on May 24, 2021, and the Jefferies Virtual Healthcare Conference on June 2, 2021. Key executives, including Frank Laukien and Mark Munch, will present. Live webcasts and replays will be accessible on the Investor Relations section of Bruker's website for 30 days post-event.